Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.
Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts.
Cancer Epidemiol Biomarkers Prev. 2019 Apr;28(4):798-806. doi: 10.1158/1055-9965.EPI-18-0863. Epub 2018 Dec 27.
Modified median and subgroup-specific gene centering are two essential preprocessing methods to assign breast cancer molecular subtypes by PAM50. We evaluated the PAM50 subtypes derived from both methods in a subset of Nurses' Health Study (NHS) and NHSII participants; correlated tumor subtypes by PAM50 with IHC surrogates; and characterized the PAM50 subtype distribution, proliferation scores, and risk of relapse with proliferation and tumor size weighted (ROR-PT) scores in the NHS/NHSII.
PAM50 subtypes, proliferation scores, and ROR-PT scores were calculated for 882 invasive breast tumors and 695 histologically normal tumor-adjacent tissues. Cox proportional hazards models evaluated the relationship between PAM50 subtypes or ROR-PT scores/groups with recurrence-free survival (RFS) or distant RFS.
PAM50 subtypes were highly comparable between the two methods. The agreement between tumor subtypes by PAM50 and IHC surrogates improved to fair when Luminal subtypes were grouped together. Using the modified median method, our study consisted of 46% Luminal A, 18% Luminal B, 14% HER2-enriched, 15% Basal-like, and 8% Normal-like subtypes; 53% of tumor-adjacent tissues were Normal-like. Women with the Basal-like subtype had a higher rate of relapse within 5 years. HER2-enriched subtypes had poorer outcomes prior to 1999.
Either preprocessing method may be utilized to derive PAM50 subtypes for future studies. The majority of NHS/NHSII tumor and tumor-adjacent tissues were classified as Luminal A and Normal-like, respectively.
Preprocessing methods are important for the accurate assignment of PAM50 subtypes. These data provide evidence that either preprocessing method can be used in epidemiologic studies.
中值修正和亚组特定基因中心化是通过 PAM50 分配乳腺癌分子亚型的两种必要的预处理方法。我们在护士健康研究(NHS)和 NHSII 参与者的亚组中评估了这两种方法衍生的 PAM50 亚型;通过 PAM50 与 IHC 替代物相关联的肿瘤亚型;并在 NHS/NHSII 中描述了 PAM50 亚型分布、增殖评分以及与增殖和肿瘤大小加权(ROR-PT)评分相关的复发风险。
为 882 例浸润性乳腺癌和 695 例组织学正常肿瘤相邻组织计算了 PAM50 亚型、增殖评分和 ROR-PT 评分。Cox 比例风险模型评估了 PAM50 亚型或 ROR-PT 评分/组与无复发生存(RFS)或远处 RFS 的关系。
两种方法之间的 PAM50 亚型高度可比。当将 Luminal 亚型归为一组时,PAM50 肿瘤亚型与 IHC 替代物之间的一致性提高到了中度。使用修正中值法,我们的研究包括 46%的 Luminal A、18%的 Luminal B、14%的 HER2 富集型、15%的基底样和 8%的正常样亚型;53%的肿瘤相邻组织为正常样。基底样亚型的女性在 5 年内复发率较高。HER2 富集型在 1999 年之前预后较差。
可以使用任何一种预处理方法来为未来的研究推导 PAM50 亚型。NHS/NHSII 的大多数肿瘤和肿瘤相邻组织分别被归类为 Luminal A 和正常样。
预处理方法对于准确分配 PAM50 亚型很重要。这些数据提供了证据,表明这两种预处理方法都可以用于流行病学研究。